HuGE Literature Finder
Records
1
-
1
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. The Lancet. Oncology 2015 Jun 16 (6): 686-94. Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu, Kristeleit Rebec |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 27, 2023
- Content source: